Edith Dieleman

Edith Dieleman

Auto-generated profile, based on publicly available information

Edith Dieleman

Amsterdam UMC location University of Amsterdam, Department of Radiation Oncology , Meibergdreef 9, Amsterdam , The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JDJudi van Diessen
Judi van Diessen
DRDirk De Ruysscher
Dirk De Ruysscher
JSJan-Jakob Sonke
Jan-Jakob Sonke
EDEugène Damen
Eugène Damen
KSKarolina Sikorska
Karolina Sikorska
JBJosé Belderbos
José Belderbos

7 February 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
MRMartijn van der Ree
Martijn van der Ree
EDEdith M T Dieleman
Edith M T Dieleman
JVJorrit Visser
Jorrit Visser
RPR Nils Planken
R Nils Planken
SBS Matthijs Boekholdt
S Matthijs Boekholdt
PPPieter G. Postema
Pieter G. Postema
Aims: Stereotactic arrhythmia radiotherapy (STAR) is suggested as potentially effective and safe treatment for patients with therapy-refractory ventricular tachycardia (VT). However, the current prospective knowledge base and experience with STAR is limited. In this study we aimed to prospectively evaluate the efficacy and safety of STAR.Methods and results: The StereoTactic Arrhythmia Radiotherapy in the Netherlands no.1 was a pre-post intervention study to prospectively evaluate efficacy and safety of STAR. In patients with therapy-refractory VT, the pro-arrhythmic region was treated with a 25 Gy single radiotherapy fraction. The main efficacy measure was a reduction in the number of treated VT-episodes by ≥50%, comparing the 12 months before and after treatment (or end of follow-up, excluding a 6-week blanking period). The study was deemed positive when ≥50% of patients would meet this criterion. Safety evaluation included left ventricular ejection fraction, pulmonary function, and adverse events. Six male patients with an ischaemic cardiomyopathy were enrolled, and median age was 73 years (range 54–83). Median left ventricular ejection fraction was 38% (range 24–52). The median planning target volume was 187 mL (range 93–372). Four (67%) patients completed the 12-month follow-up, and two patients died (not STAR related) during follow-up. The main efficacy measure of ≥50% reduction in treated VT-episodes at the end of follow-up was achieved in four patients (67%). The median number of treated VT-episodes was reduced by 87%. No reduction in left ventricular ejection fraction or pulmonary function was observed. No treatment related serious adverse events occurred.Conclusions: STAR resulted in a ≥ 50% reduction in treated VT-episodes in 4/6 (67%) patients. No reduction in cardiac and pulmonary function nor treatment-related serious adverse events were observed during follow-up.Clinical trial registration: Netherlands Trial Register—NL7510.

25 November 2022 in Clinical Lung Cancer
Verified
Journal Article
Open access
EDEdith Dieleman
Edith Dieleman
LWLisa van der Woude
Lisa van der Woude
RORob van Os
Rob van Os
LBLiselotte van Bockel
Liselotte van Bockel
ICIda Coremans
Ida Coremans
JBJose Belderbos
Jose Belderbos
Chemoradiotherapy (CRT) is the standard of care in inoperable non-small-cell lung cancer (NSCLC) patients, favoring concurrent (cCRT) over sequential CRT (seqCRT), with adjuvant immunotherapy in responders. Elderly and frail NSCLC patients have generally been excluded from trials in the past. In elderly patients however, the higher treatment related morbidity of cCRT, may outweigh the possible lower tumor control of seqCRT. For elderly patients with locally advanced NSCLC real-world data is essential to be able to balance treatment toxicity and treatment outcome. The aim of this study is to analyze acute toxicity and 3-month mortality of curative chemoradiation (CRT) in patients with stage III NSCLC and to analyze whether cCRT for elderly stage III NSCLC patients is safe. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R) is a national lung cancer audit that started in 2013 for patients treated with curative intent radiotherapy. All Dutch patients treated for stage III NSCLC between 2015 and 2018 with seqCRT or cCRT for (primary or recurrent) stage III lung cancer are included in this population-based study. Information was collected on patient, tumor- and treatment characteristics and the incidence and severity of acute non-hematological toxicity (CTCAE-4 version 4.03) and mortality within 3 months after the end of radiotherapy. To evaluate the association between prognostic factors and outcome (acute toxicity and mortality within 3 months), an univariable and multivariable analysis was performed. The definition of cCRT was:radiotherapy started within 30 days after the start of chemotherapy. Out of all 20 Dutch departments of radiation oncology, 19 centers participated in the registry. A total of 2942 NSCLC stage III patients were treated with CRT. Of these 67.2% (n = 1977) were treated with cCRT (median age 66 years) and 32.8% (n = 965) were treated with seqCRT (median age 69 years). Good performance status (WHO 0-1) was scored in 88.6% for patients treated with cCRT and in 71.0% in the patients treated with seqCRT. Acute nonhematological 3-month toxicity (CTCAE grade ≥3 or radiation pneumonitis grade ≥2) was scored in 21.9% of the patients treated with cCRT and in 17.7% of the patients treated with seqCRT. The univariable analysis for acute toxicity showed significantly increased toxicity for cCRT (P = .008), WHO ≥2 (P = .006), and TNM IIIC (P = .031). The multivariable analysis for acute toxicity was significant for cCRT (P = .015), WHO ≥2 (P = .001) and TNM IIIC (P = .016). The univariable analysis for 3-month mortality showed significance for seqCRT (P = .025), WHO ≥2 (P < .001), higher cumulative radiotherapy dose (P < .001), higher gross tumor volume total (P = .020) and male patients (p < .001). None of these variables reached significance in the multivariable analysis for 3-month mortality. In this national lung cancer audit of inoperable NSCLC patients, 3-month toxicity was significantly higher in patients treated with cCRT (21.9% vs. 17.7% for seqCRT) higher TNM stage IIIC, and poor performance (WHO≥2) patients.The 3-months mortality was not significantly different for tested parameters. Age was not a risk factor for acute toxicity, nor 3 months mortality.

24 July 2023 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
HZHaiyan Zeng
Haiyan Zeng
SSS. Schagen
S. Schagen
LHLizza Hendriks
Lizza Hendriks
GSGonzalo Sánchez-Benavides
Gonzalo Sánchez-Benavides
JJJ. Jaspers
J. Jaspers
NDNURIA RODRIGUEZ DE DIOS
NURIA RODRIGUEZ DE DIOS

4 September 2026 in Advances in Radiation Oncology
Verified
Journal Article
Open access
EDEdith M.T. Dieleman
Edith M.T. Dieleman
RORob M. van Os
Rob M. van Os
MKMerel Willemijn Kolff
Merel Willemijn Kolff
BMBas van der Maat
Bas van der Maat
MPMiguel Perez Y Perez
Miguel Perez Y Perez
LSLukas J.A. Stalpers
Lukas J.A. Stalpers